Published in Reproduction on September 24, 2014
The Effect of Mifepristone on Uterine Fibroids and Breast Tissue | NCT00579475
Trial of Mifepristone for Fibroids | NCT00133705
Efficacy Study of Vaginal Mifepristone to Treat Uterine Fibroids | NCT00881140
Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer | NCT01800422
BRCA1/2 and Effect of Mifepristone on the Breast | NCT01898312
Mifepristone for Treatment of Uterine Fibroids (Mifemyo) | NCT00712595
Mifepristone for Patients With Endometrial Cancer and LGESS | NCT00505739
Progesterone action in breast, uterine, and ovarian cancers. J Mol Endocrinol (2015) 0.98
Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression. Oncotarget (2015) 0.81
Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors. Mol Oncol (2016) 0.76
Endometriosis and breast cancer: A survey of the epidemiological studies. Oncol Lett (2015) 0.76
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol (2012) 8.52
Endometriosis. Lancet (2004) 8.41
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci U S A (1996) 4.33
Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science (2006) 3.26
NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. Genes Dev (2000) 2.90
Pro-senescence therapy for cancer treatment. Nat Rev Cancer (2011) 2.75
Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med (2012) 2.59
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol (2013) 2.48
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab (2012) 2.22
Inside and out: the activities of senescence in cancer. Nat Rev Cancer (2014) 1.96
CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol (2008) 1.95
Corticosteroid-induced glaucoma: a review of the literature. Eye (Lond) (2006) 1.88
RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med (1997) 1.80
The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action. J Biol Chem (1999) 1.76
Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology (2012) 1.71
Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc Natl Acad Sci U S A (2009) 1.66
New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res (1994) 1.55
Steroid and G protein binding characteristics of the seatrout and human progestin membrane receptor alpha subtypes and their evolutionary origins. Endocrinology (2006) 1.54
Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis. Fertil Steril (1991) 1.51
Treatment of endometriosis with the antiprogesterone mifepristone (RU486) Fertil Steril (1996) 1.48
Targeting the Wnt pathway in cancer: the emerging role of Dickkopf-3. Biochim Biophys Acta (2011) 1.47
Human glucocorticoid receptor beta binds RU-486 and is transcriptionally active. Mol Cell Biol (2007) 1.41
Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. Mol Cell Biol (2004) 1.40
Pharmacological targeting of endoplasmic reticulum stress signaling in cancer. Biochem Pharmacol (2012) 1.36
Selective Glucocorticoid Receptor modulators. J Steroid Biochem Mol Biol (2010) 1.35
Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Res (1987) 1.33
Antioxidant role of glutathione S-transferases: protection against oxidant toxicity and regulation of stress-mediated apoptosis. Antioxid Redox Signal (2004) 1.33
Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin Cancer Res (2013) 1.31
Heterologous expression of human mPRalpha, mPRbeta and mPRgamma in yeast confirms their ability to function as membrane progesterone receptors. Steroids (2008) 1.31
Non-genomic progesterone actions in female reproduction. Hum Reprod Update (2008) 1.31
Endometrial cancer: a review and current management strategies: part I. Gynecol Oncol (2014) 1.30
Mifepristone (RU 486)--a modulator of progestin and glucocorticoid action. N Engl J Med (1993) 1.29
When ER stress reaches a dead end. Biochim Biophys Acta (2013) 1.28
Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod (2009) 1.28
[The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy]. C R Seances Acad Sci III (1982) 1.26
Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol (2003) 1.23
Hormone response in ovarian cancer: time to reconsider as a clinical target? Endocr Relat Cancer (2012) 1.20
Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update (2005) 1.20
The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? Endocr Rev (1992) 1.19
Molecular origins for the dominant negative function of human glucocorticoid receptor beta. Mol Cell Biol (2003) 1.17
Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab (1993) 1.15
Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin Cancer Res (2007) 1.15
Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata. Eur J Obstet Gynecol Reprod Biol (2009) 1.14
Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1. J Clin Endocrinol Metab (2008) 1.14
Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertil Steril (1995) 1.14
Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab (1985) 1.14
Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol Endocrinol (2003) 1.12
The role of Xenopus membrane progesterone receptor beta in mediating the effect of progesterone on oocyte maturation. Mol Endocrinol (2006) 1.10
A single amino acid that determines the sensitivity of progesterone receptors to RU486. Science (1992) 1.10
Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer. Clin Cancer Res (2013) 1.10
Progesterone receptor blockage. Effect on uterine contractility and early pregnancy. Contraception (1985) 1.09
Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrinol Metab (1998) 1.08
Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Res (2012) 1.08
The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values. Steroids (2007) 1.08
Is progesterone a neutral or protective factor for breast cancer? Nat Rev Cancer (2014) 1.07
A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril (2007) 1.06
Progesterone receptor regulation in T47D human breast cancer cells: analysis by density labeling of progesterone receptor synthesis and degradation and their modulation by progestin. Endocrinology (1988) 1.06
Stimulation of the Raf/MEK/ERK cascade is necessary and sufficient for activation and Thr-160 phosphorylation of a nuclear-targeted CDK2. J Biol Chem (2002) 1.05
Characterization of the functional progesterone receptor in an endometrial adenocarcinoma cell line (Ishikawa): progesterone-induced expression of the alpha1 integrin. J Steroid Biochem Mol Biol (1996) 1.04
The mifepristone-misoprostol regimen for early medical abortion. Curr Womens Health Rep (2001) 1.03
Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest (2006) 1.03
Phase II study of mifepristone (RU486) in refractory ovarian cancer. Gynecol Oncol (2000) 1.03
Membrane progesterone receptor expression in mammalian tissues: a review of regulation and physiological implications. Steroids (2010) 1.03
Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1. Int J Oncol (2003) 1.01
Differential expression of progesterone receptor isoforms A and B in the normal ovary, and in benign, borderline, and malignant ovarian tumors. Jpn J Cancer Res (2002) 1.01
Antiprogestins in breast cancer treatment: are we ready? Endocr Relat Cancer (2012) 1.00
Implication of malignancy and prognosis of p27(kip1), Cyclin E, and Cdk2 expression in epithelial ovarian tumors. Gynecol Oncol (2001) 0.99
Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression. BMC Cancer (2011) 0.99
The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr Relat Cancer (2009) 0.99
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 0.97
Inhibition of endometrial cancer cell lines by mifepristone (RU 486). J Soc Gynecol Investig (1999) 0.97
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy. BMC Cancer (2012) 0.97
Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum Reprod (1994) 0.96
Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Semin Reprod Med (2010) 0.96
Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res Treat (1998) 0.95
The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bull Cancer (1987) 0.95
Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. Clin Cancer Res (2004) 0.94
Restriction point control of the mammalian cell cycle via the cyclin E/Cdk2:p27 complex. FEBS J (2009) 0.93
Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment. Int J Oncol (2009) 0.93
Endometrial cancer: a review and current management strategies: part II. Gynecol Oncol (2014) 0.93
Effect of reproductive hormones on ovarian epithelial tumors: I. Effect on cell cycle activity. Cancer Biol Ther (2002) 0.92
Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21. Mol Endocrinol (1997) 0.92
Molecular determinants of context-dependent progesterone receptor action in breast cancer. BMC Med (2014) 0.92
Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol (1996) 0.92
Response of human ovarian carcinoma cell lines to antiprogestin mifepristone. Oncogene (1996) 0.92
Reversal of antiprogestin resistance and progesterone receptor isoform ratio in acquired resistant mammary carcinomas. Breast Cancer Res Treat (2008) 0.92
RU486-induced growth inhibition of human endometrial cells. Fertil Steril (2000) 0.92
Glucocorticoid receptor antagonists. Curr Top Med Chem (2008) 0.92
Tracking progesterone receptor-mediated actions in breast cancer. Pharmacol Ther (2013) 0.91
The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Hum Reprod (2008) 0.91
Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res (1989) 0.90
Growth factor-dependent induction of p21(CIP1) by the green tea polyphenol, epigallocatechin gallate. Cancer Lett (2000) 0.90
Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4, and LNCaP-C4-2 prostate cancer models in nude mice. Prostate (2000) 0.90
Molecular mechanism of RU 486 action: a review. Mol Cell Biochem (1992) 0.90